Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allegra OTC Unlikely To Be In Sanofi-Aventis’ Future Plans

This article was originally published in The Tan Sheet

Executive Summary

Sanofi-Aventis reiterated its position that an Rx-to-OTC switch of Allegra (fexofenadine) would be the company's least-preferred option for the non-sedating antihistamine going forward

You may also be interested in...

Allegra-D 24 Hour approval

FDA clears Allegra-D 24 Hour Extended Release Tablets (fexofenadine HCl 180mg/ pseudoephedrine HCl 240mg) Oct. 19. The once-daily oral dose treats "seasonal allergy symptoms with nasal congestion in adults and children 12 years of age and older," FDA says. Aventis submitted the NDA for Allegra-D 24 Hour in December 2003, according to the firm's 1website...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts